ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cetuximab

Also written as “cetuximab”, “RPH-002” and “Cetuximab + Irinotecan”.

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms · Neoplasms, led by 26 companies.

Drug pageCetuximab: every studyMany companies study it; this page follows only the 90 they lead. All 565 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jun 4, 200390 company-led studies, 13 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly300 open or runningphase 3since Jun 4, 2003Apr 30, 2002none ahead
Merck KGaA, Darmstadt, Germanyits history only170 open or runningphase 3since Sep 7, 2005Jul 28, 2005none ahead
Pfizerits history only53 open or runningphase 3since Oct 5, 2020Dec 1, 2010Dec 31, 2029phase 2 · NCT05226871
Bristol-Myers Squibbits history only40 open or runningphase 3since Nov 17, 2017Jan 7, 2008none ahead
Hoffmann-La Rocheits history only41 open or runningphase 2since Dec 18, 2007Jul 3, 2007Aug 31, 2030phase 1 · NCT04929223
R-Pharmits history only40 open or runningphase 3since Feb 20, 2026Sep 28, 2006none ahead
Sarah Cannon Research Instituteits history only41 open or runningphase 3since Nov 9, 2005Nov 2, 2005none ahead
Merckits history only22 open or runningphase 3since May 21, 2025May 21, 2025Mar 28, 2029phase 3 · NCT06997497
Novartisits history only20 open or runningphase 2since May 16, 2012May 24, 2007none ahead
Pierre Fabreits history only20 open or runningphase 2since Sep 17, 2018Sep 17, 2018none ahead

Also a collaborator on its studies: Ono Pharmaceutical, AstraZeneca, Prologue Research International, Sanofi and Merck, S.L., Spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Apr 30, 2002.

  1. May 6, 2005Phase 1 study in NeoplasmsNCT00110357 · 48 enrolled · United States
  2. Jun 1, 2005Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00112346 · 120 enrolled · United States, Canada
  3. Jun 1, 2005Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00112294 · 755 enrolled · United States
  4. Sep 9, 20054 phase 1 studiesNCT00162318, NCT00207155, NCT00207116 and 1 more
  5. Sep 9, 2005Phase 2 study in Mucinous Gastrointestinal AdenocarcinomaNCT00162110 · 40 enrolled · United States
  6. Jun 20, 2006Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00343291 · 121 enrolled · United States
  7. Aug 8, 2006Phase 2 study in Colorectal NeoplasmsNCT00362102 · 38 enrolled
  8. Jun 16, 2008Phase 2 study in Advanced CancerNCT00698841 · 79 enrolled · United States, Puerto Rico
  9. Oct 6, 2008Phase 2 study in Lung NeoplasmsNCT00768131 · United States
  10. Mar 20, 2009Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00867009 · 113 enrolled · Austria, Germany, Greece and more
  11. Jan 20, 2010Phase 2 study in Head and Neck NeoplasmsNCT01057589 · 66 enrolled · Belgium, France, Germany and more
  12. Feb 3, 2010Phase 2 study in Head and Neck NeoplasmsNCT01063075 · 34 enrolled · United States, Canada
  13. Mar 3, 20103 phase 2 studies in Head and Neck NeoplasmsNCT01081041, NCT01087970, NCT01099358
  14. Apr 22, 2010Phase 2 study in Lung NeoplasmsNCT01109524 · 72 enrolled · United States, Canada, Puerto Rico
  15. Dec 9, 2018Named cetuximabINNProposed as its International Nonproprietary Name in WHO's List 120 · before, RPH-002

TargetBeta

EGFR →read by rule
“A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 30 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01109524Lung Neoplasms · United States, Canada, Puerto Rico2CompletedSep 201272
NCT01099358Head and Neck Neoplasms · United States, Canada2CompletedOct 201547
NCT01087970Head and Neck Neoplasms · United States2CompletedAug 201369
NCT01081041Head and Neck Neoplasms · United States, Canada, Mexico2CompletedAug 2013187
NCT01063075Head and Neck Neoplasms · United States, Canada2CompletedMay 201534
NCT01057589Head and Neck Neoplasms · Belgium, France, Germany and more2CompletedFeb 201266
NCT00867009Carcinoma, Non-Small-Cell Lung · Austria, Germany, Greece and more2CompletedMay 2011113
NCT00768131Lung Neoplasms · United States2WithdrawnOct 20080
NCT00698841Advanced Cancer · United States, Puerto Rico2CompletedFeb 201079
NCT00362102Colorectal Neoplasms2CompletedJul 200638
NCT00343291Carcinoma, Non-Small-Cell Lung · United States2CompletedMay 2010121
NCT00207155Colorectal Neoplasms · United States, Canada, Spain1CompletedFeb 2006110
NCT00207116Carcinoma, Non-Small-Cell Lung · United States1CompletedMar 2006120
NCT00207077Neoplasms · United States1CompletedMay 200733
NCT00162318Carcinoma, Non-Small-Cell Lung · United States1CompletedApr 200630
NCT00162110Mucinous Gastrointestinal Adenocarcinoma · United States2CompletedJan 200740
NCT00112346Carcinoma, Non-Small-Cell Lung · United States, Canada2CompletedDec 2006120
NCT00112294Carcinoma, Non-Small-Cell Lung · United States3CompletedApr 2007755
NCT00110357Neoplasms · United States1CompletedMar 200848
NCT00097227Carcinoma, Non-Small-Cell Lung · United States2CompletedApr 2007165
NCT00097214Carcinoma, Non-Small-Cell Lung · United States2CompletedApr 200757
NCT00095199Carcinoma, Non-Small-Cell Lung · United States, Canada3CompletedJul 2011939
NCT00083720Colorectal Neoplasms · United States, Canada2CompletedApr 200887
NCT00082212Ovarian Neoplasms · United States2TerminatedJun 200725
NCT00063388Carcinoma, Non-Small-Cell Lung · United States2CompletedJun 200566
NCT00063141Colorectal Neoplasms · United States, Australia, Austria and more3CompletedJun 20061,302
NCT00061815Colorectal Neoplasms · United States3CompletedDec 2004102
NCT00055419Colorectal Neoplasms · United States2CompletedJul 2004744
NCT00044863Colorectal Neoplasms · United States2CompletedDec 2005250
NCT00034541Carcinoma, Non-Small-Cell Lung · United States2CompletedMay 200332

How it is read

Names in the registry

  • “Cetuximab”, 57 entries
  • “cetuximab”, 11 entries
  • “RPH-002”, 2 entries
  • “Cetuximab + Irinotecan”, 2 entries
  • “Cetuximab + mFOLFOX6”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.